Serum levels of soluble CD163 and soluble CD14 following antibiotic therapy of patients with acute brucellosis

Huali Sun; Rongmeng Jiang; Bing Han; Xiufang Du; Chengjie Ma; Yanli Xu; Zhihai  Chen; Linghang Wang; Siyuan Yang; Xiao Lv; Hong Zhao; Xingwang Li

doi:10.3855/jidc.10602

Serum levels of soluble CD163 and soluble CD14 following antibiotic therapy of patients with acute brucellosis

Authors

Huali Sun Centre for Infectious Disease, Beijing Di Tan Hospital, Capital Medical University, Beijing, China
Rongmeng Jiang Centre for Infectious Disease, Beijing Di Tan Hospital, Capital Medical University, Beijing, China
Bing Han Centre for Infectious Disease, Beijing Di Tan Hospital, Capital Medical University, Beijing, China
Xiufang Du Department of Infectious Disease, the Third People’s Hospital, Linfen City, Shanxi Province, China
Chengjie Ma The Laboratory of lnfectious Diseases Centre, Beijing Di Tan Hospital, Capital Medical University, Beijing, China
Yanli Xu Centre for Infectious Disease, Beijing Di Tan Hospital, Capital Medical University, Beijing, China
Zhihai Chen Centre for Infectious Disease, Beijing Di Tan Hospital, Capital Medical University, Beijing, China
Linghang Wang The Laboratory of lnfectious Diseases Centre, Beijing Di Tan Hospital, Capital Medical University, Beijing, China
Siyuan Yang The Laboratory of lnfectious Diseases Centre, Beijing Di Tan Hospital, Capital Medical University, Beijing, China
Xiao Lv Department of Laboratory Medicine, the Third People’s Hospital, Linfen City, Shanxi Province, China
Hong Zhao Department of Laboratory Medicine, the Third People’s Hospital, Linfen City, Shanxi Province, China
Xingwang Li Centre for Infectious Disease, Beijing Di Tan Hospital, Capital Medical University, Beijing, China

DOI:

https://doi.org/10.3855/jidc.10602

Keywords:

biomarker, sCD14, sCD163, Brucellosis

Abstract

Introduction: Soluble CD163 (sCD163) and soluble CD14 (sCD14) levels, monocyte/macrophage activation markers, are elevated in patient serum during Brucella infection. The aim of this study was to measure serum sCD163 and sCD14 levels during treatment for acute brucellosis to determine whether they can be used to monitor treatment efficacy.

Methodology: Blood samples were collected from 30 patients with acute brucellosis (disease duration < 8 weeks) before and after 6 weeks of antibiotic therapy as well as from a comparison group of 28 healthy control individuals. Serum sCD163 and sCD14 levels were measured with specific, sandwich enzyme-linked immunosorbent assays. The clinical data and routine indices including C-reactive protein (CRP), erythrocyte sedimentation rates (ESR), as well as white cell counts (WBC) were also studied.

Results: Both serum sCD163 and sCD14 levels were significantly higher in patients with acute brucellosis than in healthy controls (p < 0.0001). A significant decline was observed in patients after cessation of treatment (p < 0.001), which still be significantly higher than that in healthy controls (p < 0.001). In additional, serum sCD163 levels were positively correlated with sCD14 levels; both of which were positively associated with CRP levels. However, neither sCD163 nor sCD14 levels were correlated with ESR or WBC.

Conclusions: The decline in sCD163 and sCD14 levels following antibiotic therapy may be used as a marker to assess therapeutic efficacy following treatment of acute brucellosis.

Downloads

Published

2019-08-31

How to Cite

Sun H, Jiang R, Han B, Du X, Ma C, Xu Y, Chen Z, Wang L, Yang S, Lv X, Zhao H, Li X (2019) Serum levels of soluble CD163 and soluble CD14 following antibiotic therapy of patients with acute brucellosis. J Infect Dev Ctries 13:714–719. doi: 10.3855/jidc.10602

Download Citation

Endnote/Zotero/Mendeley (RIS)

Issue

Vol. 13 No. 08: August 2019

Section

Original Articles

License

Authors who publish with this journal agree to the following terms:

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).